doxazosin has been researched along with Coronary Disease in 62 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting." | 9.08 | Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 9.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| " Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)." | 9.07 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991) |
| "This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting." | 9.07 | A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 9.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| "This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)." | 9.07 | Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991) |
| "Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients." | 9.06 | Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988) |
| "Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension." | 7.67 | Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988) |
| "Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension." | 7.67 | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 6.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 5.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
| "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was a randomized, double-blind, active, controlled clinical trial conducted to determine whether newer antihypertensive agents, including doxazosin, an alpha-blocker, differ from chlorthalidone, a diuretic, with respect to coronary heart disease (CHD) and other cardiovascular disease (CVD) events in hypertensive patients at high risk of CHD." | 5.10 | Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( , 2003) |
| " The double-blind, active-controlled component of ALLHAT was designed to determine whether the rate of the primary outcome-a composite of fatal coronary heart disease and nonfatal myocardial infarction-differs between diuretic (chlorthalidone) treatment and each of three other classes of antihypertensive drugs: a calcium antagonist (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin) in high-risk hypertensive persons ages 55 years and older." | 5.09 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Bettencourt, J; Davis, BR; Ford, CE; Furberg, CD; Geraci, TS; Kimmel, B; Kingry, C; Lusk, C; Nwachuku, C; Parks, H; Piller, LB; Pressel, SL; Simpson, LM; Wright, JT, 2001) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting." | 5.08 | Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. ( Levenstein, M; Levy, D; Walmsley, P, 1996) |
| "The long-term efficacy and safety of once-daily treatment with doxazosin or atenolol were compared in a 5-year study in patients with mild-to-moderate hypertension." | 5.08 | A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. ( Daae, LN; Westlie, L, 1998) |
| "This Latin American study assessed in the general practice setting the efficacy and tolerance of once-daily doxazosin in the treatment of mild or moderate essential hypertension (sitting diastolic blood pressure, 95 to 115 mm Hg)." | 5.07 | Doxazosin in the treatment of essential hypertension in general medical practice in Latin America. ( Fonseca, R; Marshall, D; Silva, H, 1991) |
| "This study was designed to assess the efficacy and tolerance of doxazosin in patients with mild, moderate, or severe essential hypertension in a general practice setting." | 5.07 | A multicenter study of doxazosin in the treatment of essential hypertension in France. ( Bonnet, G, 1991) |
| "This study was designed to investigate the efficacy and toleration of once-daily doxazosin in the treatment of essential hypertension (sitting diastolic blood pressure 95 to 115 mm Hg) in a general medical practice." | 5.07 | Clinical experience with doxazosin in general medical practice in The Netherlands. ( Harmse, DP, 1991) |
| "A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension." | 5.07 | Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension. ( Fonseca, R; López, B; Lugo de Franco, V; Medina, O; Monsalve, P; Ostojich, K; Pérez Acuña, F; Torres, N; Vera, O, 1991) |
| " Forty-two patients, ages 42 to 65 years, including 21 men with sustained hypertension and elevated serum cholesterol levels, were included in a trial of monotherapy with doxazosin administered once daily (range, 1 to 16 mg)." | 5.07 | Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol. ( Taylor, SH, 1991) |
| "In an open, non-comparative, multicenter trail performed by general practitioners, the efficacy and safety of doxazosin, an inhibitor of postsynaptic alpha 1-adrenoceptors, were studied in 924 patients with mild to moderate hypertension." | 5.07 | [Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin]. ( Ganzinger, U; Hitzenberger, G, 1993) |
| "The antihypertensive efficacy and safety of doxazosin (once daily) and prazosin (twice daily) were compared in patients with mild or moderate essential hypertension (diastolic blood pressure [DBP] 95 to 114 mm Hg) not adequately controlled by diuretics and beta-blockers." | 5.07 | A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics. ( de Planque, BA, 1991) |
| "This study investigated the safety and efficacy of doxazosin treatment in a large population of patients (n = 336) with essential hypertension and assessed the effect of doxazosin on the serum lipid profile and the calculated risk of developing coronary heart disease." | 5.07 | Clinical experience with doxazosin in general medical practice in New Zealand. ( Maslowski, AH, 1991) |
| "The efficacy and toleration of doxazosin and atenolol were compared over a 52-week period in a double-blind, multicenter study of 228 patients with mild-to-moderate hypertension." | 5.06 | Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients. ( Daae, L; Talseth, T; Vatle, S; Westlie, L, 1988) |
| "Doxazosin is a selective alpha 1-inhibitor for the reduction of calculated coronary heart disease (CHD) risk in hypertensive patients." | 5.06 | Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction. ( Guerrasio, E; Mazzola, C, 1988) |
| "Doxazosin, a selective alpha 1-inhibitor, was assessed in 34 patients with mild and moderate hypertension." | 3.67 | Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice. ( van den Hogen, AL, 1988) |
| "The antihypertensive efficacy, lipid effects, and safety of doxazosin, a selective alpha 1-inhibitor for the reduction of coronary heart disease (CHD) risk in hypertensive patients, was assessed in a general medical practice setting." | 3.67 | Clinical experience with doxazosin in general medical practice. ( Rosenthal, J, 1988) |
| "Although the pathology of essential hypertension is still unclear, studies have shown that doxazosin, a selective alpha 1-inhibitor, is able to effectively control mild-to-moderate hypertension." | 3.67 | Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. ( Rosenthal, J, 1988) |
| "The impact of treating hypertension on coronary artery disease has been less than anticipated from epidemiologic studies of cardiovascular risk factors." | 2.67 | Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group. ( Carruthers, G; Dessain, P; Fodor, G; Newman, C; Palmer, W; Sim, D, 1993) |
| "Because coronary heart disease is known to have many causes, primary preventive therapy must logically go beyond the relatively simple goal of lowering blood pressure." | 2.66 | Effects of oral antihypertensive agents on blood lipid levels. ( Leren, P, 1986) |
| " It is readily absorbed, with high bioavailability and a relatively long plasma half-life, neither of which property is influenced by age." | 2.38 | Clinical pharmacotherapeutics of doxazosin. ( Taylor, SH, 1989) |
| "Doxazosin appears to inhibit the development of CHD on two fronts." | 2.38 | Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. ( Pool, JL, 1991) |
| "Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 1.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (32.26) | 18.7374 |
| 1990's | 28 (45.16) | 18.2507 |
| 2000's | 13 (20.97) | 29.6817 |
| 2010's | 1 (1.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, BR | 5 |
| Kostis, JB | 1 |
| Simpson, LM | 2 |
| Black, HR | 1 |
| Cushman, WC | 1 |
| Einhorn, PT | 1 |
| Farber, MA | 1 |
| Ford, CE | 4 |
| Levy, D | 2 |
| Massie, BM | 1 |
| Nawaz, S | 1 |
| Lynch, AI | 1 |
| Eckfeldt, JH | 2 |
| Boerwinkle, E | 2 |
| Leiendecker-Foster, C | 2 |
| Arnett, DK | 2 |
| Wepner, U | 1 |
| Kuwajima, I | 1 |
| Miller, MB | 1 |
| Black, H | 1 |
| Pool, JL | 3 |
| Hitzenberger, G | 1 |
| Ganzinger, U | 1 |
| Carruthers, G | 1 |
| Dessain, P | 1 |
| Fodor, G | 1 |
| Newman, C | 1 |
| Palmer, W | 1 |
| Sim, D | 1 |
| Walmsley, P | 1 |
| Levenstein, M | 1 |
| Daae, LN | 1 |
| Westlie, L | 3 |
| Calò, L | 1 |
| Davis, PA | 1 |
| Cantaro, S | 1 |
| Bonfante, L | 1 |
| Castrignano, R | 2 |
| Carraro, G | 1 |
| D'Angelo, A | 2 |
| Einecke, D | 1 |
| Miller, JL | 1 |
| Ball, SG | 1 |
| Koval, PG | 1 |
| McDiarmid, T | 1 |
| Messerli, FH | 1 |
| Grossman, E | 1 |
| Schillaci, G | 1 |
| Verdecchia, P | 1 |
| Pressel, SL | 1 |
| Wright, JT | 1 |
| Geraci, TS | 1 |
| Kingry, C | 1 |
| Piller, LB | 1 |
| Bettencourt, J | 1 |
| Kimmel, B | 1 |
| Lusk, C | 1 |
| Parks, H | 1 |
| Nwachuku, C | 1 |
| Furberg, CD | 1 |
| Barzilay, JI | 1 |
| Jones, CL | 1 |
| Basile, JN | 1 |
| Goff, DC | 1 |
| Ciocon, JO | 1 |
| Sweeney, ME | 1 |
| Randall, OS | 1 |
| Westby, J | 4 |
| Birkeland, S | 3 |
| Lekven, J | 4 |
| Grong, K | 4 |
| de Planque, BA | 1 |
| McInnes, GT | 1 |
| Passarelli, P | 1 |
| Galiè, N | 1 |
| Limonetti, P | 1 |
| Branzi, A | 1 |
| Magnani, B | 1 |
| Hexeberg, E | 1 |
| Olweus, J | 1 |
| Myking, OL | 1 |
| Holme, I | 1 |
| Fauchald, P | 1 |
| Rugstad, HE | 1 |
| Stokke, HP | 1 |
| Langdon, CG | 1 |
| Naber, FB | 1 |
| Talseth, T | 2 |
| Daae, L | 2 |
| Wessels, F | 1 |
| Maslowski, AH | 1 |
| Silva, H | 1 |
| Fonseca, R | 2 |
| Marshall, D | 1 |
| Bonnet, G | 1 |
| Harmse, DP | 1 |
| Monsalve, P | 1 |
| Vera, O | 1 |
| Pérez Acuña, F | 1 |
| Medina, O | 1 |
| Ostojich, K | 1 |
| López, B | 1 |
| Torres, N | 1 |
| Lugo de Franco, V | 1 |
| Taylor, SH | 3 |
| Hernandez Hernandez, R | 1 |
| Guerrero Pajuelo, JR | 1 |
| Carvajal, AR | 1 |
| Armas Padilla, MC | 1 |
| Armas de Hernandez, MJ | 1 |
| Barragan, O | 1 |
| Boada Boada, JJ | 1 |
| Kvitting, P | 2 |
| Lenz, ML | 1 |
| Taylor, AA | 1 |
| Mohanlal, RW | 1 |
| Mauve, I | 1 |
| van der Valk, L | 1 |
| Bruschke, AV | 1 |
| van der Laarse, A | 1 |
| Leren, P | 1 |
| van den Hogen, AL | 1 |
| Rosenthal, J | 2 |
| Bartels, AC | 1 |
| de Vries, PM | 1 |
| Oe, LP | 1 |
| van Bronswÿk, H | 1 |
| Donker, AJ | 1 |
| Réveillaud, RJ | 1 |
| Fillastre, JP | 1 |
| Zech, P | 1 |
| Pati, T | 1 |
| Al Awady, M | 1 |
| Tronca, R | 1 |
| Crepaldi, G | 1 |
| Vatle, S | 1 |
| Mazzola, C | 1 |
| Guerrasio, E | 1 |
| Nechwatal, W | 1 |
| Berger, J | 1 |
| Blumrich, W | 1 |
| Bouzo, H | 1 |
| Brandl, K | 1 |
| Braun, S | 1 |
| Laukaitis, A | 1 |
| Müller, G | 1 |
| Ryba, W | 1 |
| Schreiegg, J | 1 |
| Lindner, UK | 1 |
| von Manteuffel, GE | 1 |
| Stafunsky, M | 1 |
| Englert, RG | 1 |
| Mauersberger, H | 1 |
| Hansson, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for doxazosin and Coronary Disease
| Article | Year |
|---|---|
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
The value of alpha-blockers in the management of hypertension: a practical view.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Doxazosin; | 1991 |
Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
Topics: Antihypertensive Agents; Cholesterol; Clinical Trials as Topic; Coronary Disease; Doxazosin; Humans; | 1991 |
Clinical pharmacotherapeutics of doxazosin.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Hemodynamics; Humans; Hypertension; Prazo | 1989 |
Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Dose-Response Relationship, | 1988 |
Implications of doxazosin therapy on risk of coronary heart disease.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Lipoprot | 1988 |
30 trials available for doxazosin and Coronary Disease
| Article | Year |
|---|---|
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll | 2012 |
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Chlorthalidone; Coronary Dise | 2003 |
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Chlorthalido | 2007 |
[Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; Female; | 1993 |
Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension. The Alpha Beta Canada Trial Group.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Doxazos | 1993 |
Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Dis | 1996 |
A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood | 1998 |
Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Coronary Disease; Diabetes Me | 1998 |
[ALLHAT Study: doxazosin arm is discontinued. Alpha blocker is less effective than a diuretic].
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chlorthalidone; Coronary Dis | 2000 |
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adverse Drug Reaction Reporting Systems; Antihypertensive Agents; Cause of Death; Coronary Disease; | 2001 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
A double-blind comparative study of doxazosin and prazosin when administered with beta-blockers or diuretics.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Coronary Disease; Diuretics; Double-Blind Meth | 1991 |
[Comparative effects of doxazosin and enalapril in patients with arterial hypertension and exercise-induced acute myocardial ischemia].
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Enalapril; | 1991 |
Preliminary results of the Norwegian doxazosin postmarketing surveillance study: a twelve-week experience.
Topics: Antihypertensive Agents; Blood Pressure; Cholesterol; Coronary Disease; Doxazosin; Female; Heart Rat | 1991 |
Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
Topics: Antihypertensive Agents; Cholesterol; Cohort Studies; Coronary Disease; Doxazosin; England; Family P | 1991 |
An open, noncomparative study of doxazosin in essential hypertension: experience in general practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up.
Topics: Antihypertensive Agents; Atenolol; Cholesterol; Coronary Disease; Double-Blind Method; Doxazosin; Fe | 1991 |
Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
Topics: Antihypertensive Agents; Coronary Disease; Double-Blind Method; Doxazosin; Enalapril; Family Practic | 1991 |
Clinical experience with doxazosin in general medical practice in New Zealand.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Doxazosin in the treatment of essential hypertension in general medical practice in Latin America.
Topics: Antihypertensive Agents; Argentina; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Femal | 1991 |
A multicenter study of doxazosin in the treatment of essential hypertension in France.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; France; | 1991 |
Clinical experience with doxazosin in general medical practice in The Netherlands.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; Family Practice; Female; Humans; | 1991 |
Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
Topics: Antihypertensive Agents; Cardiomegaly; Cholesterol; Coronary Disease; Doxazosin; Echocardiography; F | 1991 |
Efficacy and safety of doxazosin in the treatment of patients with mild or moderate essential hypertension and elevated levels of cholesterol.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Doxazosin; England; Female; Humans; Hyperten | 1991 |
Evidence of an antiplatelet aggregation action of doxazosin in patients with hypertension: an ex vivo study.
Topics: Antihypertensive Agents; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Doxazosin; | 1991 |
Effects of oral antihypertensive agents on blood lipid levels.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cl | 1986 |
Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Coronary D | 1988 |
Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pres | 1988 |
A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
26 other studies available for doxazosin and Coronary Disease
| Article | Year |
|---|---|
[Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2003 |
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
Topics: Coronary Disease; Doxazosin; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance | 1994 |
Doxazosin dropped from ALLHAT study.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Coronary Disease; D | 2000 |
Discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Heart Failure; Humans | 2000 |
How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Coronary Disease; Diuretics; | 2000 |
Doxazosin arm of the ALLHAT study discontinued: how equal are antihypertensive drugs? Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Transmural heterogeneity of postjunctional alpha 2 adrenergic coronary vasoconstriction in hypoperfused cat left ventricle.
Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Cats; Coronary Disease; Coronary Vessels; Doxaz | 1992 |
Management of coronary heart disease risk factors in hypertensive patients: clinical experience with doxazosin. A symposium. London, England, January 26, 1990. Proceedings.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1991 |
Blood flow regulation during acute regional ischemia in feline hearts: importance of postjunctional alpha 1- and alpha 2-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Animals; Benzazepines; Catecholamines; Cats; Coronary Circulation; Cor | 1991 |
Regional perfusion in hearts with acute coronary artery occlusion and subsequent beta 2- and alpha 1-adrenergic blockade.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cats; Coronary Circulation; Coro | 1990 |
Hypertension, coronary risk and alpha-blockade.
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Fact | 1990 |
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
Topics: Adrenergic alpha-Antagonists; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dox | 1990 |
Does alpha 1-adrenergic blockade influence regional blood flow regulation in hearts with coronary artery occlusion?
Topics: Animals; Atenolol; Cats; Coronary Circulation; Coronary Disease; Doxazosin; Female; Male; Prazosin; | 1989 |
Delayed recovery of homogeneous perfusion distribution in isolated rat heart after vasodilatation induced by alpha 1 adrenoceptor blockade during postischaemic reperfusion.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Doxazosin; L-Lactate Dehydroge | 1989 |
Alpha-blockade for hypertension: indifferent past, uncertain future.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Drug Evaluation; Humans; Hypertension; Prazosi | 1989 |
[Reduction of coronary risk factors with selective alpha-blockers. International Doxazosin Symposium. Frankfurt/Main, 7 June 1986].
Topics: Adrenergic alpha-Antagonists; Coronary Disease; Doxazosin; Humans; Prazosin; Risk | 1986 |
Doxazosin in the treatment of mild and moderate essential hypertension in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Clinical experience with doxazosin in general medical practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Coronary Disease; Doxazosin; Dru | 1988 |
Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Disease | 1988 |
A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 1988 |
A symposium: Doxazosin: coronary artery disease risk factor management. June 7, 1986, Frankfurt, Germany.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk | 1987 |
Doxazosin: A distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Proceedings of a symposium. Hamburg, West Germany, January 30, 1988.
Topics: Antihypertensive Agents; Coronary Disease; Doxazosin; Humans; Hypertension; Prazosin; Risk Factors | 1988 |